AbbVie seeks EMA approval for Skyrizi subcutaneous induction in Crohn’s disease

Reuters2026/08/27 06:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

AbbVie filed with the EMA seeking approval for SKYRIZI subcutaneous induction in adults with moderately to severely active Crohn’s disease.
Submission backed by Phase 3 AFFIRM data; the drug already has EU approval for Crohn’s disease with IV induction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CG34511) on August 27, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

AbbVie seeks EMA approval for Skyrizi subcutaneous induction in Crohn’s disease

You may also like

Crypto prices